Trial pipeline · NCT06326359
Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia
Not applicable Not yet recruiting status last verified 2024-03
A registered clinical trial, reproduced from its ClinicalTrials.gov record. Every value on this page is a field on that record. Nothing on this page is a finding, an assessment or a recommendation.
The registered record
- Accession number
- NCT06326359
- Lead sponsor
- Sohag University (other)
- Registered condition naming hair loss
- Androgenic Alopecia
- Official title
- Evaluation of Safety and Efficacy of Autologous Stromal Vascular Fraction Derived From Denovo Versus Platelet Rich Plasma Enhanced Donner Site in Treatment of Male Androgenic Alopecia
Interventions
- Procedureautologous stromal vascular fraction
Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.
Design
- Study type
- interventional
- Phase
- Not applicable
- Allocation
- randomized
- Masking
- single
- Primary purpose
- treatment
- Enrolment
- 40 participants (estimated)
What it measures
hair density
Time frame: at baseline and at 6 month after treatment
hair shaft thickness
Time frame: at baseline and at 6 month after treatment
Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.
Who can take part
- Sex
- male
- Age
- 18 Years to 55 Years
- Healthy volunteers
- accepted
A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.
Registered dates
- Study start
- March 2024 (estimated)
- Primary completion
- October 2024 (estimated)
- Study completion
- October 2026 (estimated)
- First posted
- 22 March 2024 (actual)
- Last update posted
- 22 March 2024 (actual)
"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: a primary completion registered as 2024-10 is a month, and rendering it as 1 October 2024 would invent a day the sponsor did not register.
Results
This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.
On this site
Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.
Androgenetic Alopecia: Complete GuideNew Hair Loss Treatments in Clinical Trials: Clascoterone, Pyrilutamide and What the Published Data Actually ShowComplete Guide to Finasteride for Hair LossMinoxidil 5% Complete Guide: How to Apply for Best Results
Where this came from
Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.
Open NCT06326359 on ClinicalTrials.gov · All 157 trials in the pipeline